Status: Recruiting
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Participants needed: 880
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Diwakar DavarUpdated: Apr 16, 2026Locations: 1
Eligibility criteria
Able to understand and willing to sign a written informed consent document. [+14]
Participant unable to receive nivolumab (or pembrolizumab) due to prior allergic... [+2]